Browsing: pill

It sounds like something out of a utopian vision of the future from a 1970s science-fiction movie: What if you could reap all the benefits of exercise without lifting a finger? Or, more accurately, you lift a finger to pop a pill that produces some of exercise’s benefits without ever actually moving? A drug that…

Scientists might be inching closer to a breakthrough that some of us lazy bums would very much appreciate: a pill that can safely provide the same healthy benefits of exercise

Boulder, Colorado-based Enveda has reported Phase I results for ENV-308, an oral small molecule designed to mimic Lac-Phe, a hormone the body produces during high-intensity exercise, positioning the drug as a potential maintenance therapy for patients who discontinue GLP-1 receptor agonists and subsequently regain weight

On August 10, Eli Lilly and Company (NYSE:LLY)’s weight-loss pill Foundayo won approval in the UK, becoming the first country in Europe to clear the drug for both weight management and type 2 diabetes. It’s only the second GLP-1 pill approved in Europe, arriving two months after Novo Nordisk A/S (NYSE:NVO)’s Wegovy pill got its…

FDA approved the Wegovy pill, the first oral semaglutide for weight management, in late December 2025, and it became available to patients in early January 2026. The response was immediate. Patients who had spent months dreading their weekly injections suddenly had a new question for their doctors, and doctors suddenly had a much harder question…

News Sports News NFL News “It’s a tough pill to swallow”: Travis Kelce opens up on “failing” as a leader as concerns loom over his fitness Trending Amit Bhatia India Vs Wales Kush Maini PV Sindhu “It’s a tough pill to swallow”: Travis Kelce opens up on “failing” as a leader as concerns loom over…

Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>

Eli Lilly and Company (NYSE:LLY) cleared a notable regulatory hurdle on August 10, when Britain’s drug regulator authorized the company’s oral GLP-1 drug orforglipron, becoming the first country in Europe to approve the pill. Shares of LLY increased more than 2% in response to the announcement, a modest but insightful reaction for a company whose…

The approval of an oral version of Wegovy in the EU could broaden the impact of GLP-1 medicines on the food and beverage industry, as easier access to weight-management treatment potentially brings more consumers into a market already showing changes in appetite, purchasing behavior, and nutritional priorities

Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market’s thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly (NYSE:LLY) like a winner-takes-all fight. The obesity market could top $100 billion annually by 2030, and different…